Dr. Zhaoyuan Chen 

Phrontline Biopharma Co-founder & CEO

Dr. Chen has an extensive experience in antibody-drug conjugate (ADC) drug discovery and development. Before founding Phrontline in early 2022, Dr Chen is the ADC platform head of Innovent Biologics (Suzhou China) where he helped set up the ADC platform from ground up for the company and was responsible for several ADC programs in discovery and moving a program to IND enabling study. Before that, he has worked about six years in ADC discovery at Regeneron Pharmaceuticals (New York, USA), where he participated in a variety of ADC programs including several bispecific ADC programs, such as REGN5093M114 in phase I/II in clinics. Dr. Chen received a BS degree in Chemistry from Xiamen University (Xiamen, China) and a PhD degree in Biochemistry from Brigham Young University (Utah USA).

Dr. Siyi Hu

Phrontline Biopharma Co-founder & Biology VP

Dr. Hu has nearly twenty years of experience in antibody discovery and biological drug development. Before joining Phrontline as co-founder and biology VP, he was director of antibody discovery at Innovent Biologicals (Suzhou) Co. He led a group of 20+ scientists to delivery monoclonal antibodies for 20+ targets, and led 3 INDs of bispecific antibodies for oncology and eye diseases. Before that, he was associate director of gene medicine department at Anhui Ankebio (Group) Co., where he led PD-1 program from preclinical to phase I, and contributed trastuzumab biosimilar from clinical to commercial in China. He was awarded “Hundred Talent Program in Hefei” in 2014. Dr. Hu received biology Ph.D. from University of Science and Technology of China and finished postdoc training in Emory University and Louisiana State University. 

Dr. Yanli Mao

Phrontline Biopharma Co-founder & Chemistry VP

At PhrontlineBio, Dr. Mao has been focusing on the design, synthesis and validation of linker payloads and committed to constructing the platform of linkerpayloads. Prior to co-founding PhrontlineBio in 2022, Dr. Mao led a research group at wuxiapptec to work for MNCs like Pfizer and Amegen, dedicated to providing library design and synthesis for drug discovery from hits to leads. He was also involved in the development of ADCs at Hengrui pharma. Dr. Mao gained some experience in linker payloads IND enabling as well when He was working in Chempartner. Dr. Mao received his PhD in Chemical Biology from Nanyang Technological University and got further trained as a Postdoc in CNRS (Toulouse University) in France and National University of Singapore, respectively.